Annexon surges 48% after scheduling update for Guillain-Barré Syndrome drug data
Annexon shares rose 46% to $6.70 after hours as the company said it will present topline Phase 3 results for one of its flagship programs on Tuesday morning.
—————
Boost Internet Speed–
Free Business Hosting–
Free Email Account–
Dropcatch–
Free Secure Email–
Secure Email–
Cheap VOIP Calls–
Free Hosting–
Boost Inflight Wifi–
Premium Domains–
Free Domains
